Cardiogenic shock - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Disease Reportscardiogenic shock

MeSH D012770 - cardiogenic shock

Favorite

Competitive Landscape

Events Timeline

Commercial

Clinical Trials

Competitive landscape

D009203:Myocardial infarction

$

Success rate

$

Success rate

Cardiogenic shock

$

Success rate

Events Timeline

Commercial

Company Name	Drug Name	Trade Name	Patent Expires	Approval Date	Revenue	Period
Eli Lilly	Glucagon	Baqsimi		2019-12-16	$652.8 M	Q2/23-Q3/24
Eli Lilly	Glucagon	Glucagon		1982-01-01

1

2

3

>

Clinical Trials

Historical Success Rate

Phase 1

0%

0/0

Phase 2

80%

4/5

Phase 3

47%

7/15

Approved: 4Overall Success rate: 0%

All Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Company name

Phase 1

Phase 2

Phase 3

Phase 4

Drug Name

1

2

>

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use